OHSU Knight Cancer Institute

242 total trials 201 currently recruiting 22 completed

Trial Pipeline

RECRUITING Early Phase 1

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

NCT07089940

RECRUITING Phase 2

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

NCT07228273

RECRUITING Phase 2

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

NCT06895473

RECRUITING Phase 1

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

NCT06357676

RECRUITING

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

NCT06784167

RECRUITING Phase 2

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

NCT06504459

RECRUITING NA

Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial

NCT06673095

RECRUITING Phase 1

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

NCT06357182

RECRUITING Phase 2

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

NCT05705492

RECRUITING Phase 4

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

NCT05919329

RECRUITING Phase 2

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

NCT06067438

RECRUITING Phase 1

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

NCT06249191

RECRUITING NA

CREATE: Art for Children With Cancer

NCT06342453

RECRUITING Phase 1

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

NCT06320405

RECRUITING

Use Of Indocyanine Green In Pancreas Surgery

NCT06084013

RECRUITING Phase 2

EMBRACE: Exercising Together

NCT06049355

RECRUITING NA

Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE

NCT06011499

RECRUITING

Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas

NCT05937776

RECRUITING Phase 1

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT05943496

RECRUITING

Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer

NCT06562777

RECRUITING NA

Impact of Dietary Fiber Supplementation on Colonic Microbiome

NCT05643859

RECRUITING NA

Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool

NCT05407168

RECRUITING Phase 1

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

NCT04872790

RECRUITING

Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer

NCT05081024

RECRUITING Phase 1

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

NCT04659616

RECRUITING NA

Identifying and Caring for Individuals With Inherited Cancer Syndrome

NCT04494945

RECRUITING Early Phase 1

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

NCT04005690

RECRUITING Phase 2

Feasibility of FMISO in Brain Tumors

NCT03649880

RECRUITING NA

War on Melanoma™ Public Health & Education Campaign

NCT04611568

RECRUITING Phase 2

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System

NCT03270059

ACTIVE NOT RECRUITING Phase 2

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

NCT06630325

ACTIVE NOT RECRUITING

BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy

NCT06335966

ACTIVE NOT RECRUITING Phase 2

Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma

NCT06157099

ACTIVE NOT RECRUITING Phase 4

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

NCT05722925

ACTIVE NOT RECRUITING NA

Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation

NCT04969978

ACTIVE NOT RECRUITING Phase 1

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

NCT05396859

ACTIVE NOT RECRUITING Phase 1

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT05034627

ACTIVE NOT RECRUITING Phase 2

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT04850599

ACTIVE NOT RECRUITING NA

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study

NCT04993313

ACTIVE NOT RECRUITING Phase 2

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

NCT04539808

ACTIVE NOT RECRUITING Phase 2

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

NCT04251715

ACTIVE NOT RECRUITING NA

Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer

NCT04946279

ACTIVE NOT RECRUITING Phase 2

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

NCT04267887

ACTIVE NOT RECRUITING Phase 1

TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

NCT04104139

ACTIVE NOT RECRUITING Early Phase 1

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

NCT03960177

ACTIVE NOT RECRUITING NA

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

NCT03699995

ACTIVE NOT RECRUITING Phase 1

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

NCT03361436

ACTIVE NOT RECRUITING Phase 1

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

NCT02522715

ACTIVE NOT RECRUITING Phase 2

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

NCT02312557

COMPLETED NA

Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients

NCT04172493

COMPLETED NA

Whole Body Vibration for the Improvement of Health and Functioning in Participants With Chemotherapy-Induced Peripheral Neuropathy

NCT04170075

COMPLETED NA

Exercising Together During Radiation Treatment

NCT03418025

COMPLETED NA

Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy

NCT03135782

COMPLETED NA

Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease

NCT02890979

COMPLETED Phase 1

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT02503358

COMPLETED NA

Exercise and Nutrition Program in Improving Physical Activity and Dietary Behavior in Non-Active, Overweight, or Obese Latinas

NCT03028935

COMPLETED Phase 1

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

NCT02779283

COMPLETED Phase 1

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

NCT02504359

COMPLETED Phase 2

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

NCT02099864

COMPLETED NA

Esophageal Cytology With FISH in Detecting Esophageal Cancer

NCT02100189

COMPLETED Phase 2

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

NCT02050919

COMPLETED Phase 3

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

NCT01539317

COMPLETED

Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis

NCT01556503

COMPLETED NA

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

NCT00627276

COMPLETED Phase 2

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00425386

COMPLETED Phase 2

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

NCT00381862

COMPLETED Phase 2

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00331409

COMPLETED NA

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

NCT00103038

COMPLETED Phase 1

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

NCT00053248

COMPLETED Phase 2

Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

NCT00238199

COMPLETED Phase 2

Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma

NCT00074191

What the Pipeline for OHSU Knight Cancer Institute Shows

According to the ClinicalTrials.gov registry, OHSU Knight Cancer Institute is linked to 242 US clinical trials across every stage of research activity. Of those, 201 studies are currently recruiting — about 83% of the sponsor's indexed portfolio — and 22 are already marked complete, representing roughly 9% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for OHSU Knight Cancer Institute reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 127 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for OHSU Knight Cancer Institute is Acute Myeloid Leukemia with 6 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial